Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial

Fineline Cube Sep 12, 2023

Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...

Company Drug

Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial

Fineline Cube Sep 12, 2023

Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...

Company Deals

Wecare Medical Secures Pre-Series A Funding to Advance Brain Health Technology

Fineline Cube Sep 12, 2023

Hangzhou-based Wecare Medical, a developer of brain disease diagnosis, monitoring, and treatment products, has reportedly...

Company Deals

Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17

Fineline Cube Sep 12, 2023

The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of...

Policy / Regulatory

China Updates Narcotics and Psychotropic Substances Catalog, Adds Three Substances

Fineline Cube Sep 12, 2023

The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...

Company Drug

Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials

Fineline Cube Sep 12, 2023

China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase...

Company Deals

Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds

Fineline Cube Sep 12, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA: 688131) has...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for HRS-7450 Acute Ischemic Stroke Study

Fineline Cube Sep 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17

Fineline Cube Sep 12, 2023

Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...

Company

Merck & Co. Becomes First Multinational to Register Unit in Hainan’s Lecheng Pilot Zone

Fineline Cube Sep 12, 2023

US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has officially registered a...

Company Drug

Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study

Fineline Cube Sep 12, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval...

Company Drug

ImmuneOnco’s IMM2510 and IMM27M Achieve Milestones in Phase I Clinical Trials

Fineline Cube Sep 12, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the completion of patient enrollment for...

Company Drug

CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod

Fineline Cube Sep 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy...

Company Deals

Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs

Fineline Cube Sep 11, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to...

Company Deals

Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million

Fineline Cube Sep 11, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company Medical Device

Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder

Fineline Cube Sep 11, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies

Fineline Cube Sep 11, 2023

Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the...

Company Deals

GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline

Fineline Cube Sep 11, 2023

China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB...

Company Deals

Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening

Fineline Cube Sep 11, 2023

Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection,...

Company Drug

Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval

Fineline Cube Sep 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Posts pagination

1 … 528 529 530 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.